Iovance Biotherapeutics (IOVA) Competitors $2.64 +0.06 (+2.33%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.85 -0.79 (-29.81%) As of 06:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. AKRO, ACLX, ACAD, VKTX, SWTX, SRRK, PTCT, PTGX, MLTX, and AAPGShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Scholar Rock (SRRK), PTC Therapeutics (PTCT), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Its Competitors Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics SpringWorks Therapeutics Scholar Rock PTC Therapeutics Protagonist Therapeutics MoonLake Immunotherapeutics Ascentage Pharma Group International Iovance Biotherapeutics (NASDAQ:IOVA) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations. Does the media favor IOVA or AKRO? In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Akero Therapeutics. MarketBeat recorded 10 mentions for Iovance Biotherapeutics and 9 mentions for Akero Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.94 beat Akero Therapeutics' score of 0.76 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IOVA or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -176.49%. Akero Therapeutics' return on equity of -15.19% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iovance Biotherapeutics-176.49% -49.71% -39.18% Akero Therapeutics N/A -15.19%-13.97% Do insiders and institutionals believe in IOVA or AKRO? 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 10.3% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, IOVA or AKRO? Iovance Biotherapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500. Do analysts rate IOVA or AKRO? Iovance Biotherapeutics presently has a consensus price target of $12.22, indicating a potential upside of 362.96%. Akero Therapeutics has a consensus price target of $81.57, indicating a potential upside of 61.69%. Given Iovance Biotherapeutics' higher probable upside, equities research analysts plainly believe Iovance Biotherapeutics is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iovance Biotherapeutics 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, IOVA or AKRO? Akero Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIovance Biotherapeutics$164.07M5.37-$372.18M-$1.24-2.13Akero TherapeuticsN/AN/A-$252.06M-$1.95-25.87 SummaryIovance Biotherapeutics beats Akero Therapeutics on 9 of the 15 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$861.55M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-2.1317.9729.8925.14Price / Sales5.37262.52421.4486.79Price / CashN/A41.8335.9458.58Price / Book1.137.238.125.59Net Income-$372.18M-$54.43M$3.26B$265.48M7 Day Performance-1.49%0.22%0.69%1.22%1 Month Performance49.15%5.59%2.48%0.39%1 Year Performance-66.75%9.98%27.93%23.47% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.59 of 5 stars$2.64+2.3%$12.22+363.0%-64.0%$861.55M$164.07M-2.13500Earnings ReportAKROAkero Therapeutics4.0212 of 5 stars$49.24-2.6%$82.50+67.5%+113.0%$3.93BN/A-25.2530Insider TradeACLXArcellx2.638 of 5 stars$70.59-1.0%$111.23+57.6%+39.8%$3.89B$107.94M-23.6180News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst RevisionACADACADIA Pharmaceuticals3.9864 of 5 stars$22.62-2.7%$28.13+24.3%+60.8%$3.79B$996.28M16.51510Trending NewsEarnings ReportAnalyst ForecastVKTXViking Therapeutics4.0066 of 5 stars$33.30-3.3%$86.92+161.0%-30.1%$3.74BN/A-21.7720SWTXSpringWorks Therapeutics0.3711 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230SRRKScholar Rock4.5522 of 5 stars$37.09-4.8%$42.67+15.0%+280.6%$3.52B$33.19M-14.66140News CoveragePositive NewsEarnings ReportAnalyst ForecastPTCTPTC Therapeutics4.505 of 5 stars$44.36-0.9%$65.77+48.3%+58.1%$3.52B$1.77B6.811,410Earnings ReportInsider TradePTGXProtagonist Therapeutics2.9632 of 5 stars$56.26+2.0%$66.10+17.5%+42.4%$3.49B$207.80M75.01120Earnings ReportAnalyst ForecastMLTXMoonLake Immunotherapeutics2.6926 of 5 stars$54.47-1.1%$73.14+34.3%+20.5%$3.49BN/A-23.682Earnings ReportAnalyst ForecastAnalyst RevisionAAPGAscentage Pharma Group InternationalN/A$39.27+3.9%N/AN/A$3.43B$134.35M0.00600Gap Up Related Companies and Tools Related Companies Akero Therapeutics Competitors Arcellx Competitors ACADIA Pharmaceuticals Competitors Viking Therapeutics Competitors SpringWorks Therapeutics Competitors Scholar Rock Competitors PTC Therapeutics Competitors Protagonist Therapeutics Competitors MoonLake Immunotherapeutics Competitors Ascentage Pharma Group International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
